Technology | Patient Positioning Radiation Therapy | September 04, 2019

Apollo MR3T Laser Receives FDA 510(k) Clearance

High-precision room laser used for patient positioning in radiation therapy in an electromagnetic environment

Apollo MR3T Laser Receives FDA 510(k) Clearance

September 4, 2019 — LAP LLC announced its Apollo MR3T positioning laser for radiation therapy has received U.S. Food and Drug Administration (FDA) 510(k) approval. The magnetic resonance (MR)-compatible room laser is currently the only product of its class approved the FDA, according to the company.

Apollo MR3T are high-precision room lasers for patient positioning in an electromagnetic environment. They are used in classical radiation therapy for patient positioning during imaging with a magnetic resonance tomograph (MRT) and in MR-guided radiation therapy with MR-LINAC (linear accelerators). During regular quality assurance (QA), test phantoms such as the newly developed Thales 3-D MR scanner, are placed quickly and easily with the help of certified lasers.

The components of the Apollo MR3T have minimal ferromagnetic properties and have no influence on the imaging. They are magnetically safe and optimally adapted to magnetic field strengths up to 3 Tesla. 

The device is available as a single laser or as a customized laser bridge to meet the requirements of any room situation. 

A high-quality aluminum housing protects the fine mechanics and optical components inside the Apollo MR3T. Break-resistant glass withstands all the stresses and strains of everyday clinical life. Even at a distance of 4 meters, the maximum width of the laser line is 1 mm. The line straightness within the line shows only submillimeter deviations even at a distance of 3 meters. The adjustment of the lasers is conveniently controlled via remote control. The fast and stepless adjustment of laser position and focus saves time for QA tasks and irradiation.

For more information: www.lap-laser.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

Professor David Sebag-Montefiore (Image courtesy of the University of Leeds)

News | Radiation Therapy | April 07, 2020
April 7, 2020 — An intern...
Eclipse v16 has received CE mark and is 510(k) pending
News | Proton Therapy | April 06, 2020
April 6, 2020 — Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technolo
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Women are more likely to be cured of cancer by radiotherapy but the side effects are worse.

Women are more likely to be cured of cancer by radiotherapy but the side effects are worse. Image by Mark Kostich

News | Radiation Therapy | March 30, 2020
March 30, 2020 — Women undergoing radiotherapy for
A new framework from an international team of experts aims to help protect patients and providers, and conserve protective equipment for frontline healthcare workers #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Prostate Cancer | March 30, 2020
March 30, 2020 — In the wake of the COVID-19 pan
Novel scanners may open door for prognostic assessment in patients receiving cochlear implants

Iva Speck, MD, explains research showing that novel, fully digital, high-resolution positron emission tomography/computed tomography imaging of small brain stem nuclei can provide clinicians with valuable information concerning the auditory pathway in patients with hearing impairment. The research is featured in The Journal of Nuclear Medicine (read more at http://jnm.snmjournals.org/content/current). Video courtesy of Iva Speck, University Hospital Freiburg, Germany.

News | PET-CT | March 26, 2020
March 26, 2020 — Novel, fully digital, high-resolution...
Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group

Age‐standardized, delay‐adjusted overall cancer incidence rates for 2012 through 2016 are illustrated among males and females by racial/ethnic group. Racial/ethnic groups are mutually exclusive. Data for the non‐Hispanic American Indian/Alaska Native (AI/AN) population are restricted to Indian Health Service Purchased/Referred Care Delivery Area (PRCDA) counties. API indicates Asian/Pacific Islander. Chart courtesy of ACS Journals 

News | Radiation Oncology | March 16, 2020
March 16, 2020 — The Ann...